Clinical Trials Logo
  1. Home
  2. Lennox-Gastaut Syndrome
  3. NCT04062981

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome Clinical Trial

Official title:
Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

Clinical Trial Summary

Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).

Clinical Trial Description

Subjects who successfully completed the YKP509C001 study and could benefit from continued exposure to carisbamate. This is an open-label (OL), multi-center study of carisbamate in subjects with LGS, with safety assessments from Baseline (Visit 1) through the early termination (ET)/end of study (EOS) visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04062981
Study type Interventional
Source SK Life Science, Inc.
Contact
Status Completed
Phase Phase 1
Start date May 3, 2019
Completion date December 14, 2022
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT02910297 - The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
Recruiting NCT05339126 - RNS System LGS Feasibility Study Phase 2
Active, not recruiting NCT03355209 - A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome Phase 3
Not yet recruiting NCT05066217 - EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox Gastaut Syndrome Phase 2
Recruiting NCT04611438 - Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome Phase 3
Completed NCT05364021 - Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies Phase 1/Phase 2
Terminated NCT03955432 - Long-term Cardiac Monitoring in Epilepsy N/A
Completed NCT02224560 - Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults Phase 3
Not yet recruiting NCT05485831 - Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY
Recruiting NCT05044819 - Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Phase 4
Not yet recruiting NCT05374824 - Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
Active, not recruiting NCT02655198 - Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy Phase 2
Completed NCT03467113 - A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol Phase 1
Completed NCT03731715 - Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome Phase 1
Recruiting NCT05219617 - Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults Phase 3
Active, not recruiting NCT03936777 - A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome Phase 3
Available NCT06149663 - Intermediate-Size Expanded Access Protocol (EAP) for LP352
Available NCT03778424 - An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
Available NCT02307578 - An Extended Access Program (EAP) for Perampanel